The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, controlled phase III global trial comparing sipuleucel‑T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer.
K. Fizazi
Consultant or Advisory Role - Dendreon (I,U)
T. Powles
Consultant or Advisory Role - Dendreon (I)
D. J. George
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Research Funding - Dendreon
C. H. Poehlein
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon